Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib vs Bendamustine + Rituximab in Untreated CLL/SLL
NCT05023980Phase 3Active, not recruiting
- Sponsor
- Loxo Oncology
- Start
- Sep 2021
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of pirtobrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Loxo Oncology. Started Sep 2021; status: active, not recruiting.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05023980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05023980.